Table 1

Patients’ characteristics

No. of patients included (np)66
No. of eyes included (n)75
Sex ratio (male/female)24 (36%)/42 (64%)
Eye ratio (OD/OS)37 (49%)/38 (51%)
Age (years) at time of IOL explantation arithmetic mean±SD (95% CI)75±12 (72.9 to 78.3)
Age male (years) at time of IOL explantation arithmetic mean±SD (95% CI)75±8 (71.7 to 78.3)
Age female (years) at time of IOL explantation arithmetic mean±SD (95% CI)76±13 (72.1 to 79.8)
IOL explantation period of study cohort11/2010–03/2018
Analysis period of opacified IOLs in study cohort03/2017–03/2018
Interval between initial IOL implantation (during cataract surgery) and explantation of opacified IOL (months) arithmetic mean (95% CI) (min/max)57.6 (50.1 to 65.1) (17/274)
Diabetes mellitus prevalence in study population (np) (male/female)19 (29%) (9/10)
No. of eyes with glaucoma11 (15%) (2 PEX, 9 POAG)
No. of eyes with uveitis3 (4%)
No. of eyes with vitreous haemorrhage5 (7%)
No. of eyes with synchysis scintillans1 (1%)
No. of eyes with previous long-term therapy with topical medications11 (15%) (7 prostaglandins, 9 beta-antagonists, 8 carbonic anhydrase inhibitors, 4 alpha-2-agonists, 1 steroids, 1 NSAID)
No. of eyes with epiretinal fibrosis1 (1%)
No. of eyes status post-ppv+silicone oil (oil tamponade still present at time of IOL explantation)3 (4%)
No. of eyes status post-ppv+gas1 (1%)
No. of eyes status postintravitreal injections5 (7%) (2 ranibizumab, 2 bevacizumab, 1 dexamethasone implant)
No. of eyes status postsynechiolysis1 (1%)
No. of eyes status postcyclophotocoagulation1 (1%)
No. of eyes status post-Nd:YAG laser posterior capsulotomy22 (29%)
  • IOL, intraocular lens; Nd:YAG, neodymium-doped yttrium aluminium garnet; No, number; NSAID, non-steroidal anti-inflammatory drugs; OD, right eye; OS, left eye; PEX, pseudoexfoliation; POAG, primary open-angle glaucoma; ppv, pars plana vitrectomy.